Making a meal of a single protein

The company has only one product, a morphogenic protein on which two partnerships were formed and a lot of its future plans are pinned. But Creative BioMolecules Inc. (CBMI, Hopkinton, Mass.), which owns a broad patent portfolio to the OP-1 protein and other morphogenic proteins, is embarking on an amibitious course of research following last week's announcement of its deal with Biogen Inc. (BGEN, Cambridge, Mass.) for renal disorders.

The BGEN deal, which includes $38.5 million up

Read the full 765 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE